AnaptysBio to Attend Key Investor Conferences in September
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company dedicated to advancing innovative immunology therapeutics, has announced its participation in several important investor conferences this September. The company's president and CEO, Daniel Faga, along with other senior management team members, will represent AnaptysBio at these events, showcasing their commitment to engaging with investors.
2024 Wells Fargo Healthcare Conference
One of the key events is the 2024 Wells Fargo Healthcare Conference, which will be held in Boston. This conference will include a fireside chat and opportunities for one-on-one meetings with investors.
Details of the Conference
The conference is scheduled for September 5th at 10:15 AM ET / 7:15 AM PT. This format provides investors with a valuable chance to hear directly from the company’s leaders about the latest developments at AnaptysBio.
Stifel 2024 Virtual Immunology and Inflammation Summit
After the Wells Fargo event, AnaptysBio will also take part in the Stifel 2024 Virtual Immunology and Inflammation Summit.
Event Overview
This summit is set for September 17th, starting at 1:30 PM ET / 10:30 AM PT. It will feature a fireside chat, allowing participants to gain insights into the latest advancements in immunology and inflammation treatments from leading experts.
2024 Cantor Fitzgerald Global Healthcare Conference
Another significant event on AnaptysBio's agenda is the 2024 Cantor Fitzgerald Global Healthcare Conference, which will take place in New York.
Highlights of the Conference
This conference is scheduled for September 18th at 9:45 AM ET / 6:45 AM PT. It will follow a similar format, including a fireside chat and one-on-one investor meetings, providing an excellent platform for the company to discuss its innovative therapeutic approaches.
Webcast Information
For those who cannot attend in person, live webcasts of the fireside chats will be available on the investor section of the AnaptysBio website. Replays of these webcasts will be accessible for at least 30 days after the events, ensuring that investors can stay updated on the company's activities.
About AnaptysBio
AnaptysBio is making strides in the biotechnology sector with its focus on immunology therapeutics. The company is actively developing immune cell modulators aimed at treating autoimmune and inflammatory diseases. Among its key candidates are two checkpoint agonists: ANB032, a BTLA agonist currently in a Phase 2b trial for atopic dermatitis, and rosnilimab, a PD-1 agonist, which is undergoing a Phase 2b trial for rheumatoid arthritis and a Phase 2 trial for ulcerative colitis.
Pipeline Overview
In addition to these programs, AnaptysBio has several promising candidates in its pipeline, including ANB033, an anti-CD122 antagonist antibody that is entering a Phase 1 trial, and ANB101, a BDCA2 modulator antibody currently in preclinical development. The company has also developed two cytokine antagonists available for out-licensing: imsidolimab, which has completed Phase 3 trials for generalized pustular psoriasis, and etokimab, which is ready for Phase 2/3 trials.
Collaborative Efforts
AnaptysBio has successfully partnered with GSK to develop various therapeutic antibodies targeting immuno-oncology, including an anti-PD-1 antagonist antibody known as Jemperli (dostarlimab-gxly) and an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889). This collaboration underscores the company’s innovative approach and dedication to advancing treatments in the immuno-oncology field.
Contact Information
For more information about AnaptysBio, investors and interested parties can reach out to:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
858.732.0178
Email: investors@anaptysbio.com
Frequently Asked Questions
What is AnaptysBio focused on?
AnaptysBio is dedicated to developing innovative immunology therapeutics aimed at treating autoimmune and inflammatory diseases.
What events is AnaptysBio participating in September?
The company will participate in the 2024 Wells Fargo Healthcare Conference, the Stifel 2024 Virtual Immunology Summit, and the 2024 Cantor Fitzgerald Global Healthcare Conference.
What are some key products in AnaptysBio's pipeline?
Key products include ANB032 and rosnilimab, both of which are currently in clinical trials for various conditions.
How can investors follow AnaptysBio's events?
Investors can follow the events through live webcasts available on the AnaptysBio investor website.
Who should be contacted for investor relations?
For inquiries related to investor communications, Nick Montemarano, Senior Director of Investor Relations, can be contacted.